Sarcoma
PRINCIPAL INVESTIGATORS
- Francisco Javier Garcia Del Muro Solans
CLINICAL RESEARCHERS
- Francesc Xavier Sanjuan Garriga
POSTDOCTORAL RESEARCHERS
- Sara Sanchez Serra
SCIENTIFIC SUPPORT
- Manuel Gris Lorente
- Maria Rosario Lopez Alemany
Cancer
Oncobell
Scientific production
5
PAPERS
Average IF: 9,34
4
LED PAPER
Average IF: 5,47
4 PUBLICATIONS IN FIRST DECILE
9 PUBLICATIONS IN FIRST QUARTILE
5 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Moraitis,I;Taelman,J;Arozamena,B;Mularoni,L;Wienskowska,O;Sanjuan Garriga,X;Arregui,L et al, Mucosal Macrophages Govern Intestinal Regeneration in Response to Injury., Gastroenterology, 2025;169(1):119-doi:10.1053/j.gastro.2025.01.252
- Garcia Muro,X;Valderrama,PB;Medina Colmenero,A;Etxaniz,O;Gironés Sarrió,R;Juan Fita,MJ;Costa García,M et al, Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial., Clin Cancer Res, 2025;31(4):659-666, doi:10.1158/1078-0432.CCR-24-2636
- Chicón Bosch,M;Sánchez Serra,S;Rosàs Lapeña,M;Costa Fraga,N;Besalú Velázquez,J;Illa Bernadí,J;Mateo Lozano,S et al, Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis., Mol. Oncol., 2025;19(4):1002-1028, doi:10.1002/1878-0261.13788
- Terradas,M;Mur,P;Moron Duran,FD;Mengod,P;Löffler,CML;Helderman,NC;Terlouw,D et al, Constitutional epimutations in LTBP4, a component of the TGF-ß signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer, Clin Epigenetics, 2025;17(1):183-183, doi:10.1186/s13148-025-01924-x
- Stelmach,R;Giannatempo,P;Nicolai,N;Garcia Del Muro,X, Management of Advanced Penile Cancer., Oncol. Res. Treat., 2025;1-13, doi:10.1159/000546246
Research highlights
PROJECTS
3 Ongoing competitive projects 2 Started clinical trials 17 Ongoing clinical trials 1 Ongoing non competitive project
PUBLISHED WORKS
1 Clinical guideline
INNOVATION
1 Patent 1 License 1 Spin off
NETWORKS
AGAUR SGR GRC
Selected projects
- ICI23/00065. Terapia de tumores de células germinales basada en linfocitos infiltrantes de tumores autólogos (ARES). Instituto de Salud Carlos III (ISCIII). Budget: 1.205.077,03€. 2024-2027. PI: FRANCISCO JAVIER GARCIA DEL MURO SOLANS.
- SGNDV-001. AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 (IHC 1+ AND GREATER. Seagen Inc. Budget: 349.209,9€. 2024- . PI: FRANCISCO JAVIER GARCIA DEL MURO SOLANS.
- BT8009-230. A RADOMIZED OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTASIC UROTHERUAK CABCER (DURAVELO-2). BYCYCLETX LIMITED. Budget: 210840€. 2024-2999. PI: FRANCISCO JAVIER GARCIA DEL MURO SOLANS.
- CPP2021-008515. TRASLACIÓN A LA CLÍNICA DE UNA NUEVA TERAPIA DIRIGIDA PARA EL TRATAMIENTO DEL SARCOMA DE EWING. Ministerio de Ciencia e Innovación. Budget: 199.904,74€. 2022-2025. PI: OSCAR MARTINEZ TIRADO.
- PID2021-122828OB-I00. Nuevas aproximaciones para frenar la progresión metastática del sarcoma de Ewing. Ministerio de Ciencia e Innovación. Budget: 193.600€. 2022-2025. PI: OSCAR MARTINEZ TIRADO.